Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesar Rodriguez

Showing results (241-250 of 256) with videos related to

Pageof 26
Sort By:
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 3, 2018
ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant SurvivorsShahrukh K Hashmi, Stephanie J Lee, Bipin N Savani, et al.
Blood Advances|November 5, 2025
Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid SuppressionJunia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman, et al.
Transplantation and Cellular Therapy|September 23, 2020
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular TherapyBhagirathbhai Dholaria, Bipin N Savani, Betty K Hamilton, et al.
Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
Cancer|September 23, 2020
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United StatesTalha Badar, Parameswaran Hari, Omar Dávila, et al.
Transplantation and Cellular Therapy|December 9, 2022
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN TrialsSaurabh Chhabra, Natalie Callander, Nicole L Watts, et al.
Blood Cancer Journal|April 22, 2024
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic riskNatalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, et al.
Blood Cancer Journal|October 16, 2024
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myelomaGliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera, et al.
Pageof 26

Showing results (241-250 of 256) with videos related to

Sort By:
Pageof 26
The Lancet. Haematology|September 14, 2023
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trialPeter M Voorhees, Douglas W Sborov, Jacob Laubach, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 3, 2018
ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant SurvivorsShahrukh K Hashmi, Stephanie J Lee, Bipin N Savani, et al.
Blood Advances|November 5, 2025
Long-term Remission After Cilta-Cel in Multiple Myeloma Is Linked to Diverse T Cells and Low Myeloid SuppressionJunia Vieira Dos Santos, David T Melnekoff, Adolfo Aleman, et al.
Transplantation and Cellular Therapy|September 23, 2020
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular TherapyBhagirathbhai Dholaria, Bipin N Savani, Betty K Hamilton, et al.
Blood|April 24, 2020
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trialPeter M Voorhees, Jonathan L Kaufman, Jacob Laubach, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
Cancer|September 23, 2020
African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United StatesTalha Badar, Parameswaran Hari, Omar Dávila, et al.
Transplantation and Cellular Therapy|December 9, 2022
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN TrialsSaurabh Chhabra, Natalie Callander, Nicole L Watts, et al.
Blood Cancer Journal|April 22, 2024
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic riskNatalie S Callander, Rebecca Silbermann, Jonathan L Kaufman, et al.
Blood Cancer Journal|October 16, 2024
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myelomaGliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera, et al.
Pageof 26